Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to people with visual disabilities who are using a screen reader; Press Control-F10 to open an accessibility menu.
Español

Place the Title here

Advanced gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC) require treatment plans that are specifically TAILORed for each patient. Understanding the impact of HER2 and the latest advancements in assessment and management are key elements to effectively target tumors and optimize outcomes in advanced GEA and BTC.

Zanidatamab is now the first FDA-approved bispecific antibody targeting HER2 in adults with previously treated unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC).

Clinical Perspective

Clinician Portal

Patient & Caregiver

Patient Portal

This activity is provided by Med Learning Group.
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Copyright © 2025 TAILOR. All Rights Reserved. Website by Divigner.

Pin It on Pinterest